Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Biogen surges 42% after stunning reversal sees it revive plans for Alzheimer's treatment

Shares of Biogen surged more than 42% on Tuesday morning after the company announced plans to seek approval for an experimental Alzheimer's treatment called aducanumab.

Investors welcomed the news. Biogen shares plummeted by 29% in March after the company said it would abandon the therapy following two failed clinical trials.

The company said it decided to revisit submitting the therapy for approval following a new analysis of the data from the failed trials and a series of discussions with the Food and Drug Administration.

Biogen's stock price charged more than 42% higher on Tuesday morning after the company said it would submit an Alzheimer's treatment for regulatory approval.

The biotechnology company said it decided to revive the experimental therapy, called aducanumab, following a new analysis of data from two failed clinical trials and a series of discussions with the Food and Drug Administration.

"We are hopeful about the prospect of offering patients the first therapy to reduce the clinical decline of Alzheimer's disease and the potential implication of these results for similar approaches targeting amyloid beta," Biogen CEO Michel Vounatsos said in a press release.

The treatment was almost abandoned in March after its major clinical trial was written off as a failure — a development that sent shares plunging 29% in a single session.

But Biogen said that it reviewed a larger data set from the trial and that the treatment showed promising results.

"Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language," the company said in the press release.

The therapy also appeared to improve patients' ability to do daily activities such as cleaning, shopping, and doing laundry, Biogen said.

After conferring with the FDA, Biogen said it intends to file an application for the treatment in early 2020.

Oct. 22, 2019

https://markets.businessinsider.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies